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EDITORIAL COMMENT
Can Euphoria Be Bad?*
Peter B. Berger, MD, FACC
Rochester, Minnesota
Mesmerized by euphoria over the promise of drug-eluting
stents, cardiologists have paid surprisingly scant attention to
the results of the Intracoronary Stenting and Angiographic
Results-Strut Thickness Effect on Restenosis Outcome
(ISAR-STEREO-2) trial since its first report in March
2002. This study randomized patients requiring stent place-
ment to the BX Velocity stent, which has “thick” (140 m)
struts, or the Multilink stent with “thin” (50 m) struts.
There was a large, clinically and statistically significant
difference in restenosis (17.9% vs. 31.4%, p  0.001) and
target vessel revascularization (12.3% vs. 21.9%, p  0.002)
favoring the Multilink stent. The lack of interest has been
surprising because the issue is of great clinical (and com-
mercial) importance, at least until drug-eluting stents be-
come available. What lies at the heart of this important
study is whether only lesion characteristics (i.e., vessel size,
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lesion length, stenosis severity, calcification, thrombus);
procedural characteristics (i.e., final luminal diameter, acute
gain, treatment length); and clinical characteristics (i.e.,
diabetes, perhaps renal insufficiency) determine the resteno-
sis rate, or whether stent type plays a role. While there are
clearly important differences between stents (profile, deliv-
erability, visibility, the ease with which equipment can be
advanced beyond them, access into side branches), many
believe that “all stents are created equal” in terms of
preventing restenosis compared with balloon angioplasty.
What fueled this belief? When only the Palmaz-Schatz
stent was available, companies seeking Food and Drug
Association (FDA) approval for their stents performed
randomized trials in the hope of proving equivalence, or
noninferiority, with the Palmaz-Schatz stent. Indeed, most
were found to be equivalent (1–5). However, the fact that
one stent, the Gianturco-Roubin 2, had a far higher
restenosis rate (47.3% vs. 20.6%, p  0.001) provided an
early clue that not all stents reduce restenosis equally (6).
Despite this, companies now need no more data to win
approval by the FDA for a new stent than favorable 30-day
event rates, despite significant variations from their
previously-approved, better-studied predecessors.
Prior to the ISAR-STEREO-2 trial, many studies com-
pared stents for their ability to prevent restenosis. Observa-
tional studies are of limited value since differences in
deliverability, degree of coverage, radio-opacity, and so forth
lead physicians to select one stent versus another for certain
lesion types, introducing bias that cannot be overcome by
statistical adjustment. However, several randomized trials
performed after the first five trials (1–5) shed light on this
issue (6–10), suggesting that the choice of stent influences
the restenosis rate to a clinically and statistically significant
degree. Several were single-center studies; one should gen-
erally be cautious when applying data from single-center
studies to practices throughout the world.
When thinking about the ISAR-STEREO-2 trial, it is
important to consider the following five questions:
1. Was the study well designed and performed?
2. Did it contain bias that influence the results?
3. Are the results consistent with prior studies?
4. Do the results support the investigators’ conclusions?
5. How should the results affect physicians’ practices?
Design and performance. In this issue of the Journal, the
Pache et al. (11) study was a nonblinded randomized trial
with wide enrollment criteria and few exclusion criteria.
There were minor imbalances in baseline characteristics
between the two groups; a small excess of chronic occlusions
in the thick-strut group (9% vs. 5%, p 0.06) was balanced
by a greater frequency of complex lesions in the thin-strut
group (82% vs. 70%, p  0.001). Although such character-
istics do influence the frequency of restenosis, these small
differences would not significantly impact the results of the
trial.
Bias. The fact that more of the thin-strut stents (12%)
failed to cross the lesion, and that physicians then switched
to the thicker-strut stent and were able to cross the lesion,
introduces bias in that more severe or complex lesions were
ultimately treated with the thicker-strut stent. However, the
data were analyzed on an intention-to-treat basis, minimiz-
ing any true differences in the frequency of restenosis
between the two stents. An analysis of the stent received was
also performed, confirming significantly less restenosis with
the thinner-strut stent.
An important confounder can be found in the mean
balloon inflation pressure within the stents. Compliance of
the delivery balloon of the thinner-strut stent is far greater.
Thus, although both stents were expanded with similar
balloon pressures (12.1 atm thin-strut stent vs. 12.3 atm
thick-strut stent, p  0.18), a 3.0 mm thin-strut stent
delivery balloon would be 3.5 mm at 12 atm, 0.4 mm larger
than a 3.0 mm thick-strut stent delivery balloon inflated to
the same pressure. If the stent-delivery balloons were also
used for post-deployment inflations, the results could cer-
tainly have been affected. The investigators indicated that
balloon inflations were performed with semicompliant bal-
loons rather than stent delivery balloons “in the large
majority of cases.” Furthermore, the maximal balloon diam-
eters they reported were measured by quantitative coronary
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angiography (QCA). Whether small differences in balloon
dimensions can be accurately detected by QCA is unclear.
Intravascular ultrasound is vastly superior at detecting small
differences in stent expansion that might result from bal-
loons with differing compliances, but intravascular ultra-
sound was performed infrequently in the ISAR-
STEREO-2 trial, and the results were not reported. In
summary, whether and to what degree differences in char-
acteristics of the delivery balloons impacted the results of
the Pache et al. study (11) cannot be determined; this is the
most important limitation of the study.
It must also be remembered that QCA is not entirely
automated but requires operator input. Physicians perform-
ing QCA analyses can generally tell the difference between
two stents on an angiogram, even if they are meant to be
blinded. This introduces additional bias, although this too is
unlikely to account for the relatively large difference in
restenosis rates seen in the trial. Furthermore, the target
vessel revascularization rates, described as being clinically
driven “in all cases,” are consistent with the reported
angiographic restenosis rates and lend validity to the differ-
ences reported by the QCA core laboratory.
Prior literature. The p value of 0.05 for the difference in
restenosis means that there is a 1 in 20 chance that the lower
restenosis rate of thin-strut stents was the play of chance.
Examination of prior studies of these stents may provide a
clue as to whether indeed chance is more or less likely than
1 in 20 to explain the observed results. The ISAR-
STEREO-2 trial was neither the first study nor the first
randomized study in which one of these two stents was
included. Table 1 lists all of the studies that included one of
these stents and QCA analyses (1,10,12–18) and shows that
the late loss associated with the BX Velocity stent in the
ISAR-STEREO-2 trial is larger than the late loss seen in
any prior studies of that stent. However, there were impor-
tant differences among these studies in clinical, angio-
graphic, and procedural characteristics that influenced late
loss and restenosis, limiting our ability to draw definite
conclusions by comparing studies. In addition, the large late
loss associated with the BX Velocity stent was “anchored” by
a correspondingly high frequency of ischemia-driven repeat
revascularization, and some prior studies of the thicker-strut
BX Velocity stent also raised concern about the degree of
late loss, angiographic restenosis, and/or target vessel revas-
cularization, suggesting the results of the ISAR-
STEREO-2 trial are unlikely to be entirely due to chance.
Investigators’ conclusions. The investigators reported that
the difference in restenosis rates was due to differences in
strut thickness. This may be true, but should be considered
hypothetical rather than proven. There are many differences
between the stents studied in the ISAR-STEREO-2 trial;
only one of them is strut thickness. The two stents studied
in the ISAR-STEREO-1 trial, the Multilink and Duet
stents, were more similar in design (except for strut thick-
ness) than those studied in the ISAR-STEREO-2 trial, and
the difference in restenosis rates in the ISAR-STEREO-1
trial likely resulted from strut thickness. However, metal
content and purity, surface area, design, delivery balloon,
degree to which the delivery balloons extend proximally and
distally, and so forth may all differ between the stents
studied in the ISAR-STEREO-2 trial, and restenosis rates
may have been influenced by these factors as well.
How should the results affect physicians’ practices?
Several important points need to be emphasized when
considering what impact the ISAR-STEREO-2 trial
should have on the practice of interventional cardiologists.
First, the thin-strut Multilink stent evaluated in the ISAR-
STEREO-2 trial is no longer available. Second, physicians
might consider the trade-off of greater ability to place a stent
versus a lower restenosis rate differently. Indeed, one of the
reasons that the Multilink was withdrawn from the market
was that it was not easy to deliver (as was apparent in the
ISAR-STEREO-2 trial), and being so thin and difficult to
see, stent dislodgement occurred more frequently than with
the BX Velocity and other currently available stents. Third,
it should not be assumed that more recent generations of
stents, even those with thinner struts than the BX Velocity,
will have a lower restenosis rate than the BX Velocity and
Table 1. Studies with Angiographic Follow-Up in Which the Multilink or BX Velocity Stents Have Been Included
ASCENT ISAR STEREO I CADILLAC WEST 1
Stent Placed Multilink Multilink Multilink Multilink
No. of Patients 518 326 1036 101
Diabetes Mellitus, % 19 17 18 11
Lesion Length, mm 10.9  6.0 13.9  7.7 NA NA
Stent Length, mm 15 NA NA NA
Reference Vessel Diameter, mm 3.02  0.47 3.1  0.47 3.0 3.03  0.42
Months to Follow-Up Angiography 6 6 6 6
Acute Gain, mm 1.72  0.43 NA NA 1.58  0.38
Late Loss, mm 0.78  0.53 0.94  0.74 NA NA
Angiographic Restenosis, % 16.0 15.0 22.2 17.0
TVR, % NA 8.6 7.2 10.8 (TLR)
Comments RCT vs. Palmaz-Schatz stent RCT vs. Duet stent Acute MI patients only European registry in patients
with stable or unstable
angina; de novo lesions
IVUS  intravascular ultrasound; MI  myocardial infarcartion; NA  not available; RCT  randomized controlled trial; TLR  target lesion revascularization; TVR  target
vessel revascularization.
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the same low restenosis rate as the Multilink stent in the
ISAR-STEREO-2 trial. That hypothesis remains to be
proven. Unfortunately, some stent sales representatives have
been using data from the ISAR-STEREO-2 trial to sup-
port sales of their stents in place of the BX Velocity,
although they have never been directly compared with it.
These considerations, among others, undoubtedly contrib-
ute to the observation that the ISAR-STEREO-2 trial has
apparently had little impact on sales of BX Velocity stents in
the U.S.
Implications for the future. The extent to which these
issues will remain relevant is unclear, since within months,
drug-eluting stents will be available in the U.S. In fact, the
first such stent likely to be approved by the FDA will elute
sirolimus from the BX Velocity, which had the high
restenosis rate in the ISAR-STEREO-2 trial. Is that
relevant? Apparently it is not.
The frequency of in-stent restenosis with the sirolimus-
eluting stent in the first-in-man experience (n  45) and
Randomized Study with the Sirolimus-Coated Bx Velocity
Balloon-Expandable Stent in the Treatment of Patients
with de Novo Native Coronary Artery Lesions (RAVEL)
trial (n  238) was 0 (17,19). In the much larger Multi-
center, Randomized, Double-Blind Study of the Sirolimus-
Coated Bx Velocity Balloon-Expandable Stent in the Treat-
ment of Patients with De Novo Native Coronary Artery
Lesions (SIRIUS) trial (n  1,058), only 2% developed
restenosis within the sirolimus-eluting stent, although an-
other 7% developed restenosis at the edge of the stent, in
most cases proximally. Some have wondered whether the
peri-stent restenosis might be due to the delivery balloon
extending 1 mm beyond the stent; this is unlikely, however,
as restenosis occurred more frequently proximally than
distally (even though vessels are usually smaller distally than
proximally) and did not occur in the RAVEL trial. “Geo-
graphic mismatch”—pre- or post-deployment balloon infla-
tions more proximal to where the stent was deployed—may
be a factor. Regardless, it appears that the thick struts of the
BX Velocity stent are not important when used as a
platform for sirolimus.
Conclusions. The ISAR-STEREO-2 trial is at least the
sixth appropriately sized randomized trial comparing stents
indicating that not all stents are equal in their ability to
reduce restenosis. More such trials should have been per-
formed when interventional cardiologists had scant data to
differentiate between bare stents. Happily, however, what
are now needed are comparisons between drug-eluting
stents, as the future of bare stents, the greatest advance in
interventional cardiology since the development of balloon
angioplasty, is not as bright as it once was.
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